Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review

Mini Rev Med Chem. 2023 Mar 2. doi: 10.2174/1389557523666230302140658. Online ahead of print.ABSTRACTDiabetes Mellitus [DM] is a long-term metabolic condition that is characterized by excessive blood glucose. DM is the third most death-causing disease, leading to retinopathy, nephropathy, loss of vision, stroke, and cardiac arrest. Around 90% of the total cases of diabetic patients have Type II Diabetes Mellitus[T2DM]. Among various approaches for the treatment of T2DM. G protein-coupled receptors [GPCRs] 119 have been identified as a new pharmacological target. GPR119 is distributed preferentially in the pancreas β-cells and gastrointestinal tract [enteroendocrine cells] in humans. GPR119 receptor activation elevates the release of incretin hormones such as Glucagon-Like Peptide [GLP1] and Glucose Dependent Insulinotropic Polypeptide [GIP] from intestinal K and L cells. GPR119 receptor agonists stimulate intracellular cAMP production via Gαs coupling to adenylate cyclase. GPR119 has been linked to the control of insulin release by pancreatic β-cells, as well as the generation of GLP-1 by enteroendocrine cells in the gut, as per In vitro assays. The dual role of the GPR119 receptor agonist in the treatment of T2DM leads to the development of a novel prospective anti-diabetic drug and is thought to have decreased the probability of inducing hypoglycemia. GPR119 receptor agonists exert their effects in one of two ways: either by promoting glucose absorption by β-cells, or b...
Source: Mini Reviews in Medicinal Chemistry - Category: Chemistry Authors: Source Type: research